Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.
复制标题
DOI：
10.1002/jlb.5ri0220-603rr
复制
发表时间：
2020-04
影响因子：
5.5
通讯作者：
Schoenberger SP
中科院分区：
文献类型：
--
作者：
Brightman SE;Naradikian MS;Miller AM;Schoenberger SP
CD4 + T细胞可通过调节树突状细胞来增强或抑制CD8 + T细胞反应。在抗肿瘤免疫的背景下，CD4 + T细胞的这种能力大大减弱。因此，在本综述中，我们将讨论通过免疫检查点阻断（ICB）、过继性细胞疗法（ACT）和肿瘤特异性疫苗（Vax）增强新抗原特异性CD4 + T细胞如何能够引发强烈的CD8 + T细胞反应。
CD4+ T cells can either bolster or constrain CD8+ T cell responses by conditioning dendritic cells. In the context of anti-tumor immunity, the capacity of CD4+ T cells to do so is greatly diminished. Thus, in this review we will discuss how augmenting neoantigen-specific CD4+ T cells via immune checkpoint blockade (ICB), adoptive cellular therapy (ACT), and tumor-specific vaccines (Vax) could lead to robust CD8+ T cell responses.